Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME

In the EMPA-REG OUTCOME trial, empagliflozin given in addition to standard of care significantly reduced cardiovascular (CV) death vs. placebo (HR 0.62; 95% CI 0.49, 0.77) in patients with type 2 diabetes (T2DM) and established CV disease. We investigated whether baseline HbA1c or change in HbA1c influenced the effect of empagliflozin on CV death.